Mammalian Cell Culture Metabolite Control Patents: Leaders & Trends 2026
- Concentrated but not locked. the top 5 assignees hold 28.4% of the 641 records in scope, and the top 10 hold 44.3% — a discernible core with a long tail behind it.
- Filing has cooled from its 2017 peak. 27 records that year against a documented -83% swing from 2021 (6) to 2024 (1), the last year the data can treat as complete.
- Bioreactor hardware is the thinnest layer. C12M (bioreactors & apparatus) sits at 18.9% of records versus 89.2% for the core C12N microorganism/genetic engineering class — most of the claim density is biological, not mechanical.
Filing growth compares 2021 (6 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 641 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Metabolite control in mammalian cell culture — keeping lactate, ammonia, glucose, glutamine, pH and redox state within workable ranges during a production run — sits at the intersection of cell-line engineering and bioprocess hardware. This landscape draws on 641 published records filed between 2015 and mid-2026 that combine culture-system language with a named metabolic control lever, filtered to the core IPC classes for cell culture, bioreactors and enzyme-based assays.
The scope favours documents that make an explicit metabolic-control claim rather than every cell-culture patent on file, so the ranking below reflects who is actively claiming control methods and media formulations, not who simply publishes the most cell-line patents overall.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology mix
Two views of the same 641-record set: how filing volume has moved year over year, and which IPC subclasses carry the claims.
A 2017 peak followed by a documented pullback
Filings hit 27 in 2017, the peak year in this dataset. The 2021-to-2024 span shows a -83% swing (6 down to 1) — the last year, 2024, is the most recent one the dataset can treat as complete, since publication typically lags filing by around 18 months and 2025-2026 counts will still fill in.
Biology-heavy, hardware-light
C12N (microorganisms & genetic engineering) touches 89.2% of the 641 records, with C07K (peptides & proteins) at 44.5% and A61K (medicinal preparations) at 35.7% close behind. C12M — the bioreactor and apparatus class — sits lowest of the group tracked here at 18.9%, and C12Q (enzyme/DNA measuring & testing) at 28.7% suggests assay methods are claimed about as often as the fermentation step itself (C12P, 29.5%).
Shares are the percentage of the 641 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Mammalian Cell Culture Metabolite Control with Eureka
This page is one run against one query. Ask Eureka your own question about mammalian cell culture metabolite control and every answer comes back with the patent numbers behind it.
Try EurekaA representative record from the set
Mammalian cell culture-produced neublastin antibodies
The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.Filed by Sinfonia Biotherapeutics AB, published 2019-06-27 as US20190194602A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20050124010A1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and opt… | 268 |
| 2 | US5888807A | Devices for maintaining and growing human stem and/or hematopoietics cells | 235 |
| 3 | US5763266A | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells | 213 |
| 4 | US20080004206A1 | Albumin fusion proteins | 206 |
| 5 | US5459069A | Device for maintaining and growing human stem and/or hematopoietics cells | 195 |
| 6 | US20080161243A1 | Albumin Fusion Proteins | 166 |
| 7 | US20080153751A1 | Albumin Fusion Proteins | 158 |
| 8 | US7429491B2 | Restricted glucose feed for animal cell culture | 131 |
| 9 | US20090269841A1 | Method and system for the production of cells and cell products and applications thereof | 130 |
| 10 | US5665562A | Devices and methods for the measurement of cellular biochemical processes | 112 |
Citation counts favour older filings simply by virtue of age in the corpus; treat them as a signal of influence on later work, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers indicate
Three read-outs from the filing and citation data that matter for a freedom-to-operate check or a build-versus-license call.
A core group, not a monopoly
The leader holds 49 records and fifth place holds 26 — a real gap, but the top 10 combined still account for less than half the field (44.3% of 641). That leaves the majority of records spread across a long tail of single- or few-filing entrants.
Recent filing has genuinely thinned
Every named assignee in the recent-momentum data shows zero filings in the latest year, and several show a -100% year-over-year drop. Because 2025-2026 records are still publishing, this reads as consolidation of activity rather than an active late surge.
Claims sit on biology, not on the reactor
Genetic and microorganism engineering claims (C12N) touch nearly nine in ten records, while bioreactor and apparatus claims (C12M) touch under one in five. Hardware-side control methods for lactate, pH or redox appear comparatively under-claimed relative to the cell-line and media side.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to mammalian cell culture metabolite control, with the prior art for and against each one.
Who is filing, and where the openings sit
The ranked leaders cluster around large biologics and biosimilar developers, with academic technology-transfer offices and foundations appearing further down the list.
A clear but not dominant leader
The top assignee's 49 records put it well ahead of fifth place at 26, but that gap narrows quickly — by tenth place the count is 19, and the field spreads into a long tail beyond that.
Collaboration is limited and concentrated
Only 10 co-assignee pairs appear in this dataset, and the strongest pairing links a major biologics developer with a biosimilar specialist. Most assignees in this field file alone rather than through joint ventures or research partnerships.
US and Europe anchor the filing map
The United States leads receiving-office counts, with the EPO and WIPO's PCT route close behind, followed by Australia, Canada and Israel. That spread points to applicants pursuing multi-jurisdiction protection rather than concentrating on a single home market.
| Assignee | Recent year | YoY |
|---|---|---|
| Biogen MA Inc | 0 | — |
| Novartis AG | 0 | — |
| Incyte Corp | 0 | — |
| Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | 0 | -100% |
| Wyeth LLC | 0 | — |
| Amgen Inc | 0 | — |
| Research Development Foundation | 0 | — |
| University of Pittsburgh – Of the Commonwealth System of Higher Education | 0 | — |
Where to take this analysis
The dataset points to a few concrete follow-ups depending on whether the goal is freedom-to-operate, licensing, or identifying a filing gap.
Check freedom-to-operate on the core biological claims
With C12N touching 89.2% of records, any new cell-line or media-engineering approach should be checked against the most-cited records in this set before development spend increases.
Run a claim comparison in EurekaEvaluate the bioreactor hardware gap
C12M's comparatively low 18.9% share suggests apparatus-side control methods for lactate, ammonia or redox have room for a differentiated first claim.
Explore white space in EurekaTrack the leaders' recent activity directly
Every top assignee shows zero filings in the latest year in this dataset; confirming whether that reflects a real pause or a publication lag is worth doing before assuming the space has gone quiet.
Monitor assignee activity in EurekaCommon questions on this landscape
This dataset ranks 100 companies by record count, with the leading assignee holding 49 of the 641 records in scope and fifth place holding 26. The top 5 combined account for 28.4% of all records and the top 10 for 44.3%, which means the field has a visible core of active filers but well over half the records sit outside that group. Any competitive read should treat this as a concentrated-but-open field rather than one dominated by a single player.
Filing peaked at 27 records in 2017 and has declined since, with a documented -83% swing from 6 records in 2021 to 1 in 2024. 2024 is the most recent year this dataset can treat as complete, because publication typically lags filing by around 18 months, so 2025 and 2026 counts are still filling in and should not yet be read as confirming a continued decline. The honest read is that activity has cooled from its 2017 high, not that it has stopped.
The dataset is filtered to C12N5/00 (cell culture and genetic engineering), C12M3/00 (bioreactors and apparatus) and C12Q1/02 (enzyme/microorganism testing methods). Within the results, C12N appears on 89.2% of the 641 records, C07K (peptides and proteins) on 44.5%, and C12M — the apparatus class most directly tied to bioreactor hardware — on only 18.9%. That spread shows most claims are written around the biological or genetic engineering side of metabolite control rather than the physical reactor system.
The clearest gap sits in bioreactor apparatus and sensing claims: C12M's 18.9% share of the 641 records is well below the 89.2% carried by the core genetic-engineering class C12N. Specific under-claimed areas include real-time redox-state sensing hardware, automated lactate-shift feedback loops, and glutamine-uptake-linked media dosing algorithms. A first claim in any of these would sit on comparatively thinner prior art than a media-composition or cell-line claim.
It is moderately concentrated: the top 5 assignees hold 28.4% of the 641 records and the top 10 hold 44.3%, with the leader at 49 records against 26 for fifth place and 19 for tenth. That leaves more than half the field spread across a long tail of assignees with far fewer filings each, including academic technology-transfer offices and foundations. Only 10 co-assignee pairs appear in the data, so most filers — including the leaders — are operating largely independently rather than through joint filings.
Research Mammalian Cell Culture Metabolite Control in depth with Eureka
Go past this page: query the whole mammalian cell culture metabolite control corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.